%0 Journal Article
%A Lavilla Olleros, Cristina
%A Ausín García, Cristina
%A Bendala Estrada, Alejandro David
%A Muñoz, Ana
%A Wikman Jogersen, Philip Erick
%A Fernández Cruz, Ana
%A Giner Galvañ, Vicente
%A Vargas, Juan Antonio
%A Seguí Ripoll, José Miguel
%A Rubio-Rivas, Manuel
%A Miranda Godoy, Rodrigo
%A Mérida Rodrigo, Luis
%A Fonseca Aizpuru, Eva
%A Arnalich Fernández, Francisco
%A Artero, Arturo
%A Loureiro Amigo, Jose
%A García García, Gema María
%A Corral Gudino, Luis
%A Jiménez Torres, Jose
%A Casas-Rojo, José-Manuel
%A Millán Núñez-Cortés, Jesús
%A SEMI-COVID-19 Network
%T Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19.
%D 2022
%U http://hdl.handle.net/10668/20414
%X To describe the impact of different doses of corticosteroids on the evolution of patients with COVID-19 pneumonia, based on the potential benefit of the non-genomic mechanism of these drugs at higher doses. Observational study using data collected from the SEMI-COVID-19 Registry. We evaluated the epidemiological, radiological and analytical scenario between patients treated with megadoses therapy of corticosteroids vs low-dose of corticosteroids and the development of complications. The primary endpoint was all-cause in-hospital mortality according to use of corticosteroids megadoses. Of a total of 14,921 patients, corticosteroids were used in 5,262 (35.3%). Of them, 2,216 (46%) specifically received megadoses. Age was a factor that differed between those who received megadoses therapy versus those who did not in a significant manner (69 years [IQR 59-79] vs 73 years [IQR 61-83]; p  There is no difference in mortality with megadoses versus low-dose, but there is a lower incidence of infectious complications with glucocorticoid megadoses.
%~